menu
    • menu

    Company profile for Tenaya Therapeutics

    NEW Drugs in Dev: 3
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tenaya’s approach involves in vivo reprogramming of resident cardiac fibroblasts into cardiomyocytes. Tenaya uses novel AAV vectors to introduce proprietary combinations of known transcription factors – genes that control cellular identity and function – to convert cardiac fibroblasts into cardiomyocytes. This can help repair the heart, reduce the scar area, and improve heart function.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tenaya TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    171 Oyster Point Blvd suite 500, South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tenayatherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tenaya-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tenaya Reports Interim MyPEAK™-1 Data Showing Cardiac Remodeling
    Tenaya Reports Interim MyPEAK™-1 Data Showing Cardiac Remodeling

    03 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/03/3305902/0/en/tenaya-therapeutics-announces-interim-data-from-mypeak-1-showing-treatment-of-mybpc3-associated-hcm-with-tn-201-gene-therapy-resulted-in-consistent-signs-of-cardiac-remodeling-and-.html

    GLOBENEWSWIRE
    03 Jun 2026
    Share Share
    Tenaya to Release New TN-201 Interim Phase 1b/2 Data for HCM
    Tenaya to Release New TN-201 Interim Phase 1b/2 Data for HCM

    02 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/02/3305618/0/en/tenaya-therapeutics-to-announce-new-interim-data-from-mypeak-1-phase-1b-2-trial-of-tn-201-for-adults-with-mybpc3-associated-hcm-on-wednesday-june-3-2026.html

    GLOBENEWSWIRE
    02 Jun 2026
    Share Share
    Tenaya Therapeutics to Attend Jefferies Healthcare Conference
    Tenaya Therapeutics to Attend Jefferies Healthcare Conference

    29 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/29/3303537/0/en/tenaya-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-2026.html

    GLOBENEWSWIRE
    29 May 2026
    Share Share
    Tenaya's RIDGE-1 TN-401 Ph 1b/2 Data Shows Arrhythmia Reduction
    Tenaya's RIDGE-1 TN-401 Ph 1b/2 Data Shows Arrhythmia Reduction

    15 May 2026

    // PRESS RELEASE

    https://investors.tenayatherapeutics.com/news-releases/news-release-details/positive-interim-data-cohorts-1-and-2-tenayas-ridgetm-1-phase

    PRESS RELEASE
    15 May 2026
    Share Share
    Tenaya Therapeutics Reports Q1 2026 Financial Results & Update
    Tenaya Therapeutics Reports Q1 2026 Financial Results & Update

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3289339/0/en/tenaya-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Tenaya Presents Phase 1b/2 Gene Therapy Data at ASGCT 2026
    Tenaya Presents Phase 1b/2 Gene Therapy Data at ASGCT 2026

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3281609/0/en/tenaya-therapeutics-announces-late-breaking-oral-presentation-of-new-clinical-data-from-ridge-1-phase-1b-2-clinical-trial-of-tn-401-gene-therapy-in-adults-with-pkp2-associated-arvc.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search